Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees309
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
When is Zai Lab's next earnings date?
What price target have analysts set for ZLAB?
5 brokerages have issued 12-month price targets for Zai Lab's stock. Their forecasts range from $36.54 to $84.00. On average, they anticipate Zai Lab's share price to reach $52.89 in the next twelve months. This suggests that the stock has a possible downside of 12.6%. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
News articles about ZLAB stock have been trending very negative on Tuesday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zai Lab earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Zai Lab.
Are investors shorting Zai Lab?
Zai Lab saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,730,000 shares, an increase of 14.6% from the January 15th total of 1,510,000 shares. Based on an average daily trading volume, of 261,700 shares, the short-interest ratio is presently 6.6 days. Approximately 2.9% of the shares of the company are short sold. View Zai Lab's Current Options Chain.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA) and The Medicines (MDCO).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by many different of institutional and retail investors. Top institutional investors include Segantii Capital Management Ltd (5.80%), Baillie Gifford & Co. (5.23%), Credit Suisse AG (2.79%), Renaissance Technologies LLC (0.54%), Jennison Associates LLC (0.44%) and Greenwoods Asset Management Ltd (0.34%).
Which institutional investors are selling Zai Lab stock?
ZLAB stock was sold by a variety of institutional investors in the last quarter, including Greenwoods Asset Management Ltd, Baillie Gifford & Co., Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Credit Suisse AG, Pictet Asset Management Ltd., Platinum Investment Management Ltd. and Victory Capital Management Inc..
Which institutional investors are buying Zai Lab stock?
ZLAB stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, Segantii Capital Management Ltd, First Trust Advisors LP, State Street Corp, Matthews International Capital Management LLC and Cubist Systematic Strategies LLC.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $60.53.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $3.52 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
